Literature DB >> 12579547

Self-administered treatment for smoking cessation.

Susan J Curry1, Evette J Ludman, Jennifer McClure.   

Abstract

Self-administered treatment for smoking cessation has the potential to reach a broad spectrum of the population of smokers. This article focuses on self-administration of behavioral and pharmacological treatments for smoking cessation. Evidence for the effectiveness of written manuals to self-administer behavioral treatment is mixed. There is no evidence that self-help manuals alone are effective. However, they do increase quit rates when combined with personalized adjuncts such as written feedback and outreach telephone counseling. Efficacy trials of first-line pharmacotherapies (nicotine gum, nicotine patch, and bupropion) result in doubling of cessation rates compared to placebo. It is difficult to evaluate the effectiveness of pharmacotherapies when self-administered under real-world conditions. The general consensus is that they improve quit rates, although poor compliance and early discontinuation reduce their effectiveness. Areas for further research include randomized trials of the use of new technologies (e.g., hand-held computers and the Internet) to disseminate self-administered treatments as well as improved surveillance of the use of self-administered treatment in population-based health surveys. Copyright 2003 Wiley Periodicals, Inc. J Clin Psychol 59: 305-319, 2003.

Entities:  

Mesh:

Year:  2003        PMID: 12579547     DOI: 10.1002/jclp.10131

Source DB:  PubMed          Journal:  J Clin Psychol        ISSN: 0021-9762


  9 in total

1.  A randomised control study of a fully automated internet based smoking cessation programme.

Authors:  L H G Swartz; J W Noell; S W Schroeder; D V Ary
Journal:  Tob Control       Date:  2006-02       Impact factor: 7.552

2.  Expectancies for cigarettes, e-cigarettes, and nicotine replacement therapies among e-cigarette users (aka vapers).

Authors:  Paul T Harrell; Nicole S Marquinez; John B Correa; Lauren R Meltzer; Marina Unrod; Steven K Sutton; Vani N Simmons; Thomas H Brandon
Journal:  Nicotine Tob Res       Date:  2014-08-28       Impact factor: 4.244

Review 3.  Adherence to Pharmacological Smoking Cessation Interventions: A Literature Review and Synthesis of Correlates and Barriers.

Authors:  Lauren R Pacek; F Joseph McClernon; Hayden B Bosworth
Journal:  Nicotine Tob Res       Date:  2018-09-04       Impact factor: 4.244

Review 4.  Tailoring nicotine replacement therapy: rationale and potential approaches.

Authors:  Jennifer B McClure; Gary E Swan
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

5.  E-cigarette use in adults: a qualitative study of users' perceptions and future use intentions.

Authors:  Vani Nath Simmons; Gwendolyn P Quinn; Paul T Harrell; Lauren R Meltzer; John B Correa; Marina Unrod; Thomas H Brandon
Journal:  Addict Res Theory       Date:  2016-02-23

6.  Acceptability and Cultural Appropriateness of Self-Help Booklets for Relapse Prevention in Puerto Rico.

Authors:  Nicole S Menzie; Vani N Simmons; Gwendolyn P Quinn; Diana B Diaz; Barbara Piñeiro; Julio Jimenez; Eida Castro; Thomas H Brandon
Journal:  J Cancer Educ       Date:  2015-09       Impact factor: 2.037

7.  A comparison of the nicotine lozenge and nicotine gum: an effectiveness randomized controlled trial.

Authors:  Quinn R Pack; Douglas E Jorenby; Michael C Fiore; Thomas Jackson; Patricia Weston; Megan E Piper; Timothy B Baker
Journal:  WMJ       Date:  2008-08

8.  Defining participant exposure measures in Web-based health behavior change programs.

Authors:  Brian G Danaher; Shawn M Boles; Laura Akers; Judith S Gordon; Herbert H Severson
Journal:  J Med Internet Res       Date:  2006-08-30       Impact factor: 5.428

9.  Pragmatic randomised trial of a smartphone app (NRT2Quit) to improve effectiveness of nicotine replacement therapy in a quit attempt by improving medication adherence: results of a prematurely terminated study.

Authors:  Aleksandra Herbec; Jamie Brown; Lion Shahab; Robert West; Tobias Raupach
Journal:  Trials       Date:  2019-09-02       Impact factor: 2.279

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.